See more : Rio Tinto Group (RIOP.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Geron Corporation (GERN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Geron Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Veg of Lund AB (publ) (VOLAB.ST) Income Statement Analysis – Financial Results
- Mestro AB (publ) (MESTRO.ST) Income Statement Analysis – Financial Results
- Kyushu Leasing Service Co., Ltd. (8596.T) Income Statement Analysis – Financial Results
- Zimmer Biomet Holdings, Inc. (ZIM.DE) Income Statement Analysis – Financial Results
- Sompo Holdings, Inc. (8630.T) Income Statement Analysis – Financial Results
Geron Corporation (GERN)
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 237.00K | 596.00K | 1.39M | 253.00K | 460.00K | 1.07M | 1.07M | 6.16M | 36.37M | 1.15M | 1.28M | 2.71M | 2.44M | 3.56M | 1.73M | 2.80M | 7.62M | 3.28M | 290.00K | 1.05M | 1.17M | 1.25M | 3.62M | 6.61M | 5.40M | 6.80M | 7.30M | 5.30M |
| Cost of Revenue | 123.74M | 868.00K | 783.00K | 50.05M | 51.27M | 12.72M | 8.44M | 14.70M | 9.57M | 8.90M | 9.13M | 25.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.65M | -3.70M | -1.70M | -1.60M | -1.20M |
| Gross Profit | -123.50M | -272.00K | 610.00K | -49.80M | -50.81M | -11.66M | -7.37M | -8.53M | 26.80M | -7.75M | -7.85M | -22.47M | 2.44M | 3.56M | 1.73M | 2.80M | 7.62M | 3.28M | 290.00K | 1.05M | 1.17M | 1.25M | 3.62M | 11.26M | 9.10M | 8.50M | 8.90M | 6.50M |
| Gross Profit Ratio | -52,110.97% | -45.64% | 43.79% | -19,683.40% | -11,046.09% | -1,093.53% | -692.21% | -138.48% | 73.68% | -671.99% | -611.93% | -829.42% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 170.40% | 168.52% | 125.00% | 121.92% | 122.64% |
| Research & Development | 125.05M | 95.52M | 85.73M | 51.49M | 52.07M | 13.43M | 11.03M | 18.05M | 17.83M | 20.71M | 23.16M | 51.37M | 69.32M | 61.69M | 57.62M | 53.66M | 54.62M | 41.23M | 35.08M | 30.08M | 25.55M | 31.57M | 29.02M | 23.55M | 20.60M | 15.60M | 15.10M | 14.30M |
| General & Administrative | 69.14M | 43.63M | 29.67M | 25.68M | 20.89M | 18.71M | 19.29M | 18.76M | 17.79M | 16.76M | 15.62M | 20.40M | 23.79M | 18.04M | 14.34M | 16.18M | 15.84M | 9.40M | 8.79M | 7.10M | 5.80M | 5.38M | 9.62M | 9.27M | 5.60M | 3.80M | 3.10M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 69.14M | 43.63M | 29.67M | 25.68M | 20.89M | 18.71M | 19.29M | 18.76M | 17.79M | 16.76M | 15.62M | 20.40M | 23.79M | 18.04M | 14.34M | 16.18M | 15.84M | 9.40M | 8.79M | 7.10M | 5.80M | 5.38M | 9.62M | 9.27M | 5.60M | 3.80M | 3.10M | 3.20M |
| Other Expenses | 0.00 | 1.00M | 1.10M | 168.00K | -69.00K | -154.00K | 0.00 | 0.00 | 1.31M | 0.00 | 0.00 | 5.45M | 5.45M | 35.00M | 57.62M | 0.00 | 54.62M | 0.00 | -5.87M | 45.15M | 0.00 | 0.00 | 0.00 | 4.65M | 3.70M | 1.70M | 1.60M | 1.20M |
| Operating Expenses | 194.18M | 139.15M | 115.39M | 77.17M | 72.97M | 32.14M | 30.32M | 36.81M | 35.62M | 37.47M | 38.78M | 71.77M | 93.11M | 79.73M | 71.96M | 69.85M | 70.46M | 50.64M | 38.00M | 37.19M | 31.35M | 36.95M | 38.64M | 37.47M | 29.90M | 21.10M | 19.80M | 18.70M |
| Cost & Expenses | 194.18M | 139.15M | 115.39M | 77.17M | 72.97M | 32.14M | 30.32M | 36.81M | 35.62M | 37.47M | 38.78M | 71.77M | 93.11M | 79.73M | 71.96M | 69.85M | 70.46M | 50.64M | 38.00M | 37.19M | 31.35M | 36.95M | 38.64M | 32.82M | 26.20M | 19.40M | 18.20M | 17.50M |
| Interest Income | 18.15M | 2.53M | 527.00K | 1.83M | 4.22M | 3.29M | 1.42M | 1.19M | 677.00K | 373.00K | 951.00K | 3.10M | 1.02M | 2.05M | 1.37M | 5.54M | 10.79M | 8.70M | 4.66M | 1.55M | 1.81M | 2.55M | 5.86M | 5.92M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.31M | 6.88M | 3.74M | 760.00K | 0.00 | 0.00 | 77.00K | 83.00K | 88.00K | 82.00K | 56.00K | 233.00K | 237.00K | 98.00K | 143.00K | 93.00K | 102.00K | 130.00K | 464.00K | 672.00K | 736.00K | 757.00K | 1.00M | 12.28M | 0.00 | 900.00K | 0.00 | 400.00K |
| Depreciation & Amortization | 1.03M | 868.00K | 783.00K | 935.00K | 776.00K | 59.00K | 76.00K | 81.00K | 56.00K | 47.00K | 320.00K | 830.00K | 1.58M | 1.61M | 1.75M | 2.42M | 1.93M | 1.59M | 3.74M | 3.91M | 4.12M | 4.59M | 4.37M | 4.65M | 3.70M | 1.70M | 1.60M | 1.20M |
| EBITDA | -174.78M | -134.15M | -111.59M | -73.92M | -67.77M | -26.96M | -29.18M | -30.57M | 803.00K | -35.62M | -38.06M | -67.82M | -95.04M | -109.67M | -68.29M | -59.91M | -62.84M | -47.36M | -35.85M | -32.23M | -26.06M | -31.11M | -30.65M | -21.56M | -17.10M | -10.90M | -9.30M | -11.00M |
| EBITDA Ratio | -73,747.68% | -22,654.19% | -8,010.70% | -29,611.46% | -15,761.96% | -3,051.88% | -2,613.99% | -477.99% | 3.92% | -3,117.00% | -2,823.46% | -2,434.81% | -3,388.72% | -1,160.74% | -4,078.27% | -2,320.37% | -1,001.86% | -1,623.19% | -13,736.21% | 1,226.97% | -2,153.24% | -2,492.79% | -517.65% | -326.21% | 116.67% | -200.00% | -152.05% | -241.51% |
| Operating Income | -193.94M | -138.55M | -114.00M | -76.91M | -72.51M | -31.07M | -29.26M | -30.65M | -559.00K | -36.31M | -38.96M | -71.76M | -96.12M | -111.17M | -70.23M | -67.04M | -62.84M | -47.36M | -37.71M | -81.29M | -30.18M | -35.70M | -35.02M | -26.21M | -20.80M | -12.60M | -10.90M | -12.20M |
| Operating Income Ratio | -81,832.91% | -23,246.64% | -8,183.70% | -30,400.40% | -15,761.96% | -2,914.92% | -2,746.95% | -497.34% | -1.54% | -3,149.35% | -3,036.48% | -2,648.87% | -3,942.41% | -3,120.04% | -4,069.18% | -2,391.87% | -824.44% | -1,445.22% | -13,003.45% | -7,719.37% | -2,570.70% | -2,860.58% | -967.38% | -396.61% | -385.19% | -185.29% | -149.32% | -230.19% |
| Total Other Income/Expenses | 9.82M | -3.35M | -2.11M | 1.30M | 3.96M | 4.06M | 1.34M | 1.11M | 605.00K | 642.00K | 579.00K | 2.88M | -737.00K | -210.00K | 50.00K | 5.02M | 26.14M | 16.00M | 4.18M | 880.00K | 297.00K | 0.00 | -11.91M | 0.00 | -23.40M | 2.70M | 1.80M | 1.80M |
| Income Before Tax | -184.13M | -141.90M | -116.11M | -75.62M | -68.55M | -27.02M | -27.92M | -29.54M | 46.00K | -35.67M | -38.38M | -68.88M | -96.85M | -111.38M | -70.18M | -62.02M | -36.70M | -31.37M | -33.53M | -80.41M | -29.88M | 0.00 | -46.93M | 0.00 | -44.20M | -9.90M | -9.10M | -10.40M |
| Income Before Tax Ratio | -77,690.72% | -23,808.89% | -8,335.39% | -29,888.14% | -14,901.74% | -2,534.43% | -2,621.22% | -479.34% | 0.13% | -3,093.67% | -2,991.35% | -2,542.67% | -3,972.64% | -3,125.93% | -4,066.28% | -2,212.67% | -481.46% | -957.13% | -11,561.38% | -7,635.80% | -2,545.40% | 0.00% | -1,296.38% | 0.00% | -818.52% | -145.59% | -124.66% | -196.23% |
| Income Tax Expense | 0.00 | -868.00K | 4.84M | -7.00K | -5.00M | 4.06M | 1.34M | 1.11M | 32.00K | 35.00K | 56.00K | -597.00K | 5.68M | 31.25M | -3.14M | -5.87M | -26.14M | -16.00M | -4.19M | 44.27M | -297.00K | -1.79M | 7.05M | 19.62M | 25.60M | -1.80M | -1.30M | -1.50M |
| Net Income | -184.13M | -141.03M | -120.95M | -75.61M | -63.55M | -27.02M | -27.92M | -29.54M | 46.00K | -35.67M | -38.38M | -68.88M | -96.85M | -111.38M | -70.18M | -62.02M | -36.70M | -31.37M | -33.53M | -80.41M | -29.88M | -33.91M | -42.07M | -45.83M | -46.40M | -10.80M | -9.60M | -10.70M |
| Net Income Ratio | -77,690.72% | -23,663.26% | -8,682.84% | -29,885.38% | -13,815.43% | -2,534.43% | -2,621.22% | -479.34% | 0.13% | -3,093.67% | -2,991.35% | -2,542.67% | -3,972.64% | -3,125.93% | -4,066.28% | -2,212.67% | -481.46% | -957.13% | -11,561.38% | -7,635.80% | -2,545.40% | -2,716.99% | -1,162.24% | -693.49% | -859.26% | -158.82% | -131.51% | -201.89% |
| EPS | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 | -0.30 | -0.54 | -0.78 | -1.14 | -0.80 | -0.79 | -0.49 | -0.47 | -0.58 | -1.79 | -0.97 | -1.37 | -1.90 | -2.20 | -3.00 | -0.94 | -0.91 | -2.08 |
| EPS Diluted | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 | -0.30 | -0.54 | -0.78 | -1.14 | -0.80 | -0.79 | -0.49 | -0.47 | -0.58 | -1.79 | -0.97 | -1.37 | -1.90 | -2.20 | -3.00 | -0.94 | -0.91 | -1.38 |
| Weighted Avg Shares Out | 570.65M | 380.78M | 327.63M | 271.46M | 190.16M | 176.50M | 159.22M | 159.05M | 158.04M | 153.54M | 127.93M | 126.94M | 124.51M | 97.60M | 88.08M | 78.19M | 74.21M | 66.06M | 57.88M | 44.88M | 30.97M | 24.66M | 22.12M | 20.87M | 15.49M | 11.44M | 10.55M | 5.15M |
| Weighted Avg Shares Out (Dil) | 570.65M | 380.78M | 327.63M | 271.46M | 190.16M | 176.50M | 159.22M | 159.05M | 162.66M | 153.54M | 128.38M | 126.94M | 124.51M | 97.60M | 88.08M | 78.19M | 74.21M | 66.06M | 57.88M | 44.88M | 30.97M | 24.66M | 22.12M | 20.87M | 15.49M | 11.44M | 10.55M | 7.74M |
Geron (GERN) Reports Q2 Loss, Lags Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.07 per share a year ago.
Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the second quarter of 2023. “We progressed our business significantly...
Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its second quarter 2023 financial results on Thursday, August 3, 2023 at 4:00 p.m. Eastern Time via press release, which will be...
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 130,050 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with...
Geron Stock: These Prices Are Unlikely To Return
After decades of work and delay, Geron Corporation is finally approaching its first approval. That should be done by about H1 2024, and although the stock looks properly valued based on revenue projections, there are other factors in play. One...
Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that an Expanded Access Protocol (EAP) is available for imetelstat, the Company's first-in-class telomerase inhibitor. As allowed under the U.S. Food and Drug Administration (FDA) policies,...
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
Longevity efforts are forefront of the news cycle today, due in large part to recent coverage of tech billionaire Bryan Johnson's unique strategy to delay aging. This has investors trying to sniff out which biotech stocks to buy.
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 72,770 shares of Geron common stock as inducements to a newly hired employee in connection with commencement of employment...
Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the submission to the United States Food and Drug Administration (FDA) of a New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in...
Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in the investigator-led Phase 2 IMpress clinical trial evaluating imetelstat, the Company's first-in-class telomerase inhibitor, in patients with acute...
Source: https://incomestatements.info
Category: Stock Reports